| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01997255 Details | 2016-05-05 Interventional | 2 | 0 | Everolimus Brain Stem Infa… Epilepsy Klippel-Trenaun… Sturge-Weber Sy… Syndrome Sturge Weber Sy… | Site did not want to pursue study - | |||
| NCT01499251 Details | 2016-05-05 Interventional | 1 | - | Macitentan Temozolomide Glioblastoma | Results did not clearly support continuing development in recurrent GBM - | |||
| NCT01110603 Details | 2016-05-05 Interventional | 1 | 12 | Carboplatin Doxorubicin Liposomal doxor… Niraparib Paclitaxel Neoplasms Cancer: Solid T… | - - | |||
| NCT00603577 Details | 2016-05-05 Interventional | 3 | 102 | Xaliproden Colorectal Neop… | development of product discontinued - | |||
| NCT02507323 Details | 2016-05-04 Interventional | 2 | 0 | Prasugrel Hydro… Ticagrelor Cardiovascular … Cardiovascular … | collaborator withdrew the study - | |||
| NCT01562951 Details | 2016-05-04 Interventional | 3 | 15 | Adalimumab Crohn Disease Inflammation Mucositis Crohn's Disease Mucosal Inflamm… | Not enough patient population according to selection criteria to complete the study - | |||
| NCT01558011 Details | 2016-05-04 Interventional | 2 | 51 | Capecitabine Docetaxel Oxaliplatin Adenocarcinoma Gastric Adenoca… | The budget issues. - | |||
| NCT00971126 Details | 2016-05-04 Interventional | 1/2 | 3 | Sorafenib Thalidomide Carcinoma Carcinoma, Hepa… Hepatocellular … | Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated
early this trial. - | |||
| NCT02463110 Details | 2016-05-03 Interventional | 4 | 2 | Sertraline Coronary Artery… Coronary Diseas… Depression Depressive Diso… Myocardial Infa… Myocardial Isch… Necrosis | Investigator's decision - | |||
| NCT01587508 Details | 2016-05-03 Interventional | 3 | 0 | Amitriptyline Cyclobenzaprine Meloxicam Low Back Pain Acute Lumbago | The comparator product was withdrawn from the brazilian market not being possible to conduct
the design regarding initially planned. - | |||
| NCT01567904 2011-005155-14 Details | 2016-05-03 Interventional | 2 | 2 | Semuloparin Thrombosis Thrombosis Prop… | Decision from Sanofi to withdraw on a worldwide basis the Marketing Authorisation Applications
for Semuloparin sodium in the adult indication - | |||
| NCT00591357 Details | 2016-05-03 Interventional | 4 | - | Antidiarrheals Loperamide Clostridium Inf… Colitis Diarrhea Antibiotic-Asso… Clostridium Dif… | Lack of personnel to complete trial - | |||
| NCT02414555 Details | 2016-05-02 Interventional | 4 | 60 | Norepinephrine Phenylephrine Vasoconstrictor… Critical Illnes… | Patient Safety - | |||
| NCT02392676 Details | 2016-05-02 Interventional | 3 | 0 | Olaparib Carcinoma, Ovar… Hypersensitivit… Ovarian Neoplas… Platinum Sensit… | Study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative
studies have the potential to meet future clinical demand. - | |||
| NCT02144753 Details | 2016-05-02 Interventional | 2 | 120 | Calcium polycar… Psyllium Constipation Irritable Bowel… Constipation-pr… | Per DSMB, study fiber had given subjects more adverse events and made their IBS symptoms worse
than the psyllium group. - | |||
| NCT02338531 2014-004358-32 Details | 2016-04-29 Interventional | 2 | 0 | Nirogacestat Breast Neoplasm… Triple Negative… Breast Cancer | Due to the discontinuation of the development of the Notch inhibitor PF-03084014-04 - | |||
| NCT01981707 2013-003058-25 Details | 2016-04-28 Interventional | 2/3 | 12 | Choline Prostatic Neopl… Prostatic Neopl… Castration-resi… | enrollment default - | |||
| NCT01697735 Details | 2016-04-28 Interventional | 4 | 24 | Atorvastatin Rosuvastatin Ca… Dyslipidemias Hyperlipidemias | Because of lack of participants and funds - | |||
| NCT02014649 Details | 2016-04-22 Interventional | 1/2 | 15 | Laninamivir Zanamivir Influenza, Huma… Influenza | Study was terminated as per BARDA decision to terminate contract. - | |||
| NCT01807156 Details | 2016-04-22 Interventional | 2 | 7 | Tivozanib Carcinoma, Hepa… Liver Neoplasms Hepatocellular … | Primary endpoint not met - |